Diabetes Therapy with Novel Agents after Heart Transplant: A Multi-Institutional Analysis

Purpose: Diabetes mellitus (DM) after heart transplant (HTx) is associated with increased risk of kidney dysfunction and cardiovascular (CV) morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel therapies shown to improve CV and metabolic outcomes, but HTx recipients were excluded from pivotal clinical trials and few data exist on their use after HTx.